Enanta Pharmaceuticals (ENTA) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Enanta Pharmaceuticals (ENTA) Receives a Hold From Leerink Partners
TipRanksJan 17 01:09 ET · Ratings
12 Health Care Stocks Moving In Thursday's Pre-Market Session
BenzingaJan 16 16:05 ET
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Enanta PharmaceuticalJan 8 00:00 ET
Sector Update: Health Care Stocks Mixed Tuesday Afternoon
MT NewswiresDec 24, 2024 12:47 ET
Top Midday Decliners
MT NewswiresDec 24, 2024 12:38 ET
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
BenzingaDec 24, 2024 09:49 ET

Comments

ApexTradeZ

Jan 5 17:20

Add to the WL 🫵🏻🥇💯

$Enanta Pharmaceuticals (ENTA.US)$
do you put much effort in the market to be early? I spend 10-16 hrs a day own (3) businesses and have a wife / (4) sons and a life but one is what they eat and i eat success and i win all the time…. find follow join and win connect to my efforts and win with me …..

thoughtful Narwhal_3

Dec 9, 2024 05:49

$Enanta Pharmaceuticals (ENTA.US)$ topline data looks good

Jaguar8

Dec 9, 2024 05:32

NEWS

$Enanta Pharmaceuticals (ENTA.US)$
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
• Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2
• Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified ...

1

This_Guy

Dec 9, 2024 05:32

$Enanta Pharmaceuticals (ENTA.US)$
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Positive
Achieved primary endpoint with 1.4 log viral load decline at Day 5 in Part 2
Demonstrated favorable safety profile with no treatment discontinuations
Received FDA Fast Track designation
Successfully achieved target drug exposure levels across all age groups
Showed 1.2 log viral loa...

Moomoo AI

Mar 5, 2024 20:53

Enanta Pharmaceuticals' P/S ratio remains low despite recent share price jump, likely due to weak revenue forecast. Market sentiment doesn't anticipate a strong share price rise soon.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

2

ENTA Enanta Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Trending Stocks